Trial
NCT02729961
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
Condition
Anaplastic Large Cell Lymphoma, ALK-Positive
Intervention
Brentuximab Vedotin
Why stopped
Administrative closure
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-10